• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Annals of Long Term Care

  • Follow us on

Search

  • Home
  • ARCHIVES
    • Issues
    • Supplements/Webcasts
  • About Us
    • Mission Statement
    • Editorial Description
    • Editorial Board
    • Publishing Staff
    • Our Partners
    • AGS Affiliations
    • Reprints/Permissions
  • SUBMIT
    • Author Guidelines
    • Copyright Transfer Form
    • Author Disclosure Form
    • Submit Now
  • CONTACT
  • ADVERTISING
    • Print Rate Card
    • Online Rate Card
    • Classified Rate Card
    • Sales Contacts
  • Supplements/Special Projects
  • Journal News
  • WEBCASTS
    • Facing Postherpetic Neuralgia in LTC
    • Treatment for Postherpetic Neuralgia Pain
    • Case Study—LTC Patient Suffering from PHN

Osteonecrosis of the Mandible in a Nursing Home Resident Receiving Bisphosphonate Therapy

  • Mon, 10/13/08 - 11:14am
  • 0 Comments
  • 6297 reads
Author(s): 

Jorge Diduszyn, MD, Margot Boigon, MD, Catherine Glew, BM, BS, CMD, and Mary T. Hofmann, MD

Case Presentation
Brief History

Mrs. O is a 71-year-old female resident of a long-term care (LTC) facility who presented in January 2007 with the chief complaint of “swelling below her chin.” The patient had been complaining of pain in her gums for several weeks. She had only two teeth remaining in her lower mandible. Given her risk factors for osteonecrosis of the jaw, she had been referred for dental evaluation a few weeks previously. A full examination and an orthopantography revealed no bone abnormalities. Her dentures were found to be ill-fitting, and recommendations for regular oral hygiene and denture refitting were made.

Mrs. O’s physician visited her emergently at the facility after a report from nursing that she had considerable swelling and redness under her chin. She was transferred to the hospital for further evaluation and treatment.

Her past medical history was significant for a nonambulatory woman with chronic obstructive pulmonary disease (COPD), anemia, mild pulmonary hypertension, obesity, venous insufficiency with lower-extremity stasis dermatitis, congestive heart failure, hypertension, atrial fibrillation, gastroesophogeal reflux disease, pancreatitis, type 2 diabetes mellitus, multiple myeloma, and osteoporosis.

The multiple myeloma was classified as Stage III. She was diagnosed in March 2005 and had begun treatment on March 12 with the following regimen: dexamethasone 40 mg intravenously (IV), given from the 1st to the 4th and from the 9th to the 12th days of each month, thalidomide 100 mg daily, and zoledronic acid 4 mg IV monthly. The multiple myeloma was under good control with this regimen (no bone pain, no renal insufficiency, and normal calcium) until January 2007, when this pain and swelling occurred.

Mrs. O’s other medications were as follows: darbepoetin alfa 300 mg intramuscularly (IM) weekly, furosemide 40 mg daily, valsartan 180 mg daily, atorvastatin 40 mg daily, sertraline 25 mg daily, sotalol 40 mg daily, fluticasone propionate/salmeterol xinafoate inhaler 250/50 twice daily, calcium carbonate with vitamin D 500 mg/400 IU twice daily, iron sulfate 325 mg 3 times daily, and warfarin 6 mg daily.

The review of systems was negative apart from the chief complaint; in particular, Mrs. O had no fever, hoarseness, dysphagia, or odynophagia. The social history was significant for remote tobacco use and very occasional social alcohol. Mrs. O was a retired teacher’s aide and had lived in the nursing facility for years.

Physical exam at the time of hospital admission was significant for slight distress due to pain. Her temperature was 99.0 degrees F; pulse was 55 beats per minute, and respirations were 18 per minute. Blood pressure was 106/85 mm Hg. Mrs. O’s cardiovascular, respiratory, gastrointestinal, and neurological exams were unremarkable. She had a purple swelling under her chin, approximately 16 cm across and localized more to her right side (Figure 1). Her submandibular/submental region was indurated, erythematous, and tender to palpation but without fluctuance or crepitus. There was swelling at the base of the tongue. She had two teeth in her left anterior lower jaw with some decay. A minute portion of the mandible was visible inside the mouth on the right anterior and left posterior lower mandible (Figure 2).

Data

The complete blood count demonstrated a hemoglobin of 9.4 g/dL and a hematocrit of 30.1%. The corpuscular indices were within normal limits; the white blood cell count was within normal limits at 10,000 with 81% neutrophils, 10% monocytes, 0% basophils, and 7% lymphocytes. The platelet count was 232 x 103/µL. Glucose was 103 mg/dL, BUN 18 mg/dL, creatinine 1.0 mg/dL, sodium 138 mEq/L, potassium 4.7 mEq/L, chloride 106 mEq/L, bicarbonate 23 mEq/L, AST and ALT 16 U/L, alkaline phosphatase 50 U/L, calcium 8.8 mg/dL, albumin 3.4 g/dL, and total protein 5.7 g/dL.

References: 

1. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575. 2. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med 2006;145:235]. Ann Intern Med 2006;144:753-761. 3. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102. 4. Bolland MJ, Grey A, Reid IR. Osteonecrosis of the jaw and bisphosphonates: Editorial was confusing. BMJ 2006;333:1122-1123. 5. Ruggiero S. Bisphosphonate-related osteonecrosis of the jaws. Compend Contin Educ Dent 2008;29(2):96-98, 100-102, 104-105. 6. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo Clinic Consensus Statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81(8):1047-1053. 7. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346(9):653-661. 8. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534. 9. Ruggiero S, Gralow J, Marx R, Hoff A, et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac 2006;2(1):7-14. 10. Looker AC, Johnston CC Jr, Wahner HW, et al. Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 1995;10:796-802. 11. Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporosis Int 1999;9(2):151-157. 12. Greenspan SL, Schneider DL, McClung MR et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long term care facilities. A randomized, double-blind, placebo controlled trial. Ann Intern Med 2002;136:742-746. 13. Edwards BJ, Migliorati CA. Osteoporosis and its implications for dental patients. J Am Dent Assoc 2008;139(5):545-552. 14. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 2006;137;1144-1150. 15. Osteonecrosis of the jaw. American Dental Association Website. www.ada.org/ prof/resources/topics/osteonecrosis.asp. Accessed August 8, 2008.

image description image description
  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »



Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
  • Use to create page breaks.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.

LATEST NEWS

  • FDA Finally Approves Once-Weekly Type 2 Diabetes Treatment
    [Amylin] 1-31-12
  • FDA approves Voraxaze to treat patients with toxic methotrexate levels
    [FDA] 1-17-12
  • FDA approves first generic version of cholesterol-lowering drug Lipitor
    [FDA] 11-30-11
  • AHRQ Awards $34 Million To Expand Fight Against Healthcare-Associated Infections
    [AHRQ] 11-17-11
more »

Poll

Are nutritional supplements underutilized in long-term care?:

Classified/Recruitment Opportunities

  • Advertise Your Job Here
more »

ALTC Blogs

How to Create Collegiality in a Difference of Opinion: Part 2

Neil Baum MD
2/6/12 | 0 Comments | 13 reads

How to Create Collegiality in a Difference of Opinion: Part 1

Neil Baum MD
2/3/12 | 0 Comments | 41 reads

Dutasteride vs Low Grade Prostate Cancer

Alvin B Lin MD FAAFP
1/31/12 | 0 Comments | 64 reads
more »
banner banner banner banner banner
HMP Communications © 2012 HMP Communications
  • Home
  • About Us
  • Other Publications
  • Contact Us
  • Privacy Policy

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. © 2012 HMP Communications